Infliximab is currently used for the treatment of inflammatory arthritic conditions and inflammatory disease with a favorable safety profile. Because of the limitations of current treatments for DME, and based on our recent findings indicating that infliximab is an effective therapy for cystoid ME associated with uveitis, we decided to assess whether infliximab is effective for patients with diabetes (type 1 or 2) and sight-threatening DME.